High and variable frequencies of CYP2C19 mutations: Medical consequences of poor drug metabolism in Vanuatu and other Pacific islands

Pharmacogenetics

Volumn 9, Issue 5, 1999, Pages 581-590

  Kaneko, Akira ^a,e   Lum, J Koji ^b   Yaviong, James ^c   Takahashi, Nobuyuki ^a   Ishizaki, Takashi ^d   Bertilsson, Leif ^e   Kobayakawa, Takatoshi ^a   Björkman, Anders ^e  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b INSTITUTE OF STATISTICAL MATHEMATICS   (Japan)

^c Malaria Section   (Vanuatu)

^d KUMAMOTO UNIVERSITY   (Japan)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

CYP2C19; Malaria; Proguanil; Vanuatu

Indexed keywords

ARTICLE; DRUG METABOLISM; FEDERATED STATES OF MICRONESIA; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENOTYPE; HUMAN; NORMAL HUMAN; PACIFIC ISLANDS; PHARMACOGENETICS; POLYNESIA; PRIORITY JOURNAL; VANUATU;

ANTIMALARIALS; ARYL HYDROCARBON HYDROXYLASES; CHILD; CHLOROGUANIDE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MIXED FUNCTION OXYGENASES; MUTATION; PACIFIC ISLANDS; PHARMACOGENETICS; SELECTION (GENETICS); VANUATU; VARIATION (GENETICS);

EID: 0032692297     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Andersson T, Regårdh C-G, Lou Y-C, Zhang Y, Dahl M-L, Bertilsson L. Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics 1992; 2:25-31.
2. Barbujani G, Sokal RR. Zones of sharp genetic change in Europe are also linguistic boundaries. Proc Natl Acad Sci USA 1990; 87:1816-1819.
3. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Clin Pharmacokinet 1995; 29:192-209.
4. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J, Villén T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 1989; 45:348-355.
5. Bertilsson L, Lou Y-Q, Du Y-L, Liu Y, Kuang T-Y, Liao X-M, et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 1992; 51:388-397.
6. Cavalli-Sforza LL, Minch E, Mountain JL. Coevolution of genes and languages revisited. Proc Natl Acad Sci USA 1992; 89:5620-5624.
7. Chen J, Sokal RR, Ruhlen M. Worldwide analysis of genetic and linguistic relationships of human populations. Hum Biol 1995; 67:595-612.
8. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
9. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994a; 269:15419-15422.
10. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994b; 46:594-598.
11. de Morais SMF, Goldstein JA. Xie H-G, Huang S-L, Lu Y-Q, Xia H, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995; 58:404-411.
12. Diamond JM. Express train to Polynesia. Nature 1988; 336:307-308.
13. Felsenstein J. PHYLIP (Phylogeny Inference Package). Version 3.5c. Distributed by the author. Seattle: Department of Genetics, University of Washington; 1993.
14. Ferguson RJ, de Morais SMF, Benhamou S, Bouchardy C, Blaisdell J, Ibeanu G, et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. J Pharmacol Exp Ther 1998; 284:356-361.
15. Flint J, Hill AVS, Bowden DK, Oppenheimer SJ, Sill PR, Serjeantson SW, et al. High frequencies of α-thalassaemia are the result of natural selection by malaria. Nature 1986; 321:744-750.
16. Furuta T, Ohashi K, Kamata T, Takashima M, Kosuge K, Kawasaki T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med 1998; 129:1027-1030.
17. Ganczakowski M, Town M, Bowden DK, Vulliamy TJ, Kaneko A, Clegg JB, et al. Multiple glucose 6-phosphate dehydrogenase-deficient variants correlate with malaria endemicity in the Vanuatu Archipelago (Southwestern Pacific). Am J Hum Genet 1995; 56:294-301.
18. Ghoneim MM, Korttila K, Chiang C-K, Jacobs L, Schoenwald RD, Mewaldt SP, Kayaba K-O. Diazepam effects and kinetics in Caucasians and Orientals. Clin Pharmacol Ther 1981; 29:749-756.
19. Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994; 33:1743-1752.
20. Goldstein JA, Ishizaki T, Chiba K, de Morais SMF, Bell D, Krahn PM, Evans DAP. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics 1997; 7:59-64.
21. Green RC. Near and Remote Oceania: disestablishing 'Melanesia' in cultural history. In: Pawley A, editor. Man and a half: essays in Pacific anthropology and ethnobotony in honour of Ralph Bulmer. Auckland: The Polynesian Society: 1991. pp. 491-502.
22. Grimes JE, Grimes B. editors. Ethnologue language family index. 13th edn. Dallas: Summer Institute of Linguistics; 1996. http://www.sil.org/ethnologue/.
23. Groube L, Chappell J, Muke J, Price D. A 40 000 year-old human occupation site at Huon Peninsula, Papua New Guinea. Nature 1986; 324:453-455.
24. Hertzberg M, Mickleson KNP, Serjeantson SW, Prior JF. Trent RJ. An Asian-specific 9-bp deletion of mitochondrial DNA is frequently found in Polynesians. Am J Hum Genet 1989; 44:504-510.
25. Horai Y, Nakano M, Ishizaki T, Ishikawa K, Zhou H-H, Zhou B-J, et al. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese. Clin Pharmacol Ther 1989; 46:198-207.
26. Ibeanu GC, Blaisdell J, Ghanayem BI, Beyeler C, Benhamou S, Bouchardy C, et al. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics 1998a; 8:129-135.
27. Ibeanu GC, Goldstein JA, Meyer U, Benhamou S, Bouchardy C, Dayer P, et al. Identification of new human CYP2C19 alleles (CYP2C19‡6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytion. J Pharmacol Exp Ther 1998b; 286:1490-1495.
28. Irwin G. The prehistoric exploration and colonization of the Pacific. Cambridge: Cambridge University Press; 1992.
29. Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin p (4′)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985; 19:483-487.
30. Kaneko A, Kaneko O, Taleo G, Björkman A, Kobayakawa T. High frequencies of CYP2C19 mutations and poor metabolism of proguanil in Vanuatu. Lancet 1997; 349:921-922.
31. Kaneko A, Taleo G, Kalkoa M, Yav̀iong J, Reeve PA, Ganczakowski M, et al. Malaria epidemiology, glucose 6-phosphate dehydrogenase deficiency and human settlement in the Vanuatu Archipelago. Acta Trop 1998; 70:285-302.
32. Kaneko A, Bergqvist Y, Takechi M, Kalkoa M, Kaneko O, Kobayakawa T, et al. Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil. J Infect Dis 1999a; 179:974-979.
33. Kaneko A, Bergqvist Y, Taleo G, Kobayakawa T, Ishizaki T, Björkman A. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations. Pharmacogenetics 1999b; 9:317-326.
34. Kirch PV, Hunt TL. Radiocarbon dates from the Mussau Islands and the Lapita colonization of the Southwest Pacific. Radiocarbon 1988; 30:161-169.
35. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin Pharmacol Ther 1996; 60:661-666.
36. Kumana CR, Lauder IJ, Chan M, Ko W, Lin HJ. Differences in diazepam pharmacokinetics in Chinese and white Caucasians-relation to body lipid stores. Eur J Clin Pharmacol 1987; 32:211-215.
37. Küpfer A, Preisig R. Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 1984; 26:753-759.
38. Lell B, Luckner D, Ndjavé M, Scott T, Kremsner PG. Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children. Lancet 1998; 351:709-713.
39. Linder MW, Prough RA, Valdes Jr R. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 1997; 43:254-266.
40. Long JC. Matrix correlation analysis. Version 1.0. Distributed by the author. Section on population genetics and Linkage. Rockville, MD: Laboratory of Neurogenetics. NIAAA/NIH; 1996.
41. Lum JK, Cann RL. mtDNA and language support a common origin of Micronesians and Polynesians in Island Southeast Asia. Am J Phys Anthropol 1998; 105:109-119.
42. Lum JK, Rickards O, Ching C, Cann RL. Polynesian mitochondrial DNAs reveal three deep maternal lineage clusters. Hum Biol 1994; 66:567-590.
43. Lum JK, Cann RL, Martinson JJ, Jorde LB. Mitochondrial and nuclear genetic relationships among Pacific Island and Asian populations. Am J Hum Genet 1998; 63:613-624.
44. Mantel N. The detection of disease clustering and a generalized regression approach. Cancer Res 1967; 27:209-220.
45. Martinson JJ. Molecular perspectives on the colonization of the Pacific. In: Boyce AJ, Macie-Taylor CGN, editors. Molecular biology and human diversity. London: Cambridge University Press; 1996. pp. 171-195.
46. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995; 57:656-661.
47. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38:402-408.
48. Nei M. Molecular evolutionary genetics. New York: Columbia University Press; 1987.
49. O'Shaughnessy DF, Hill AVS, Bowden DK, Weatherall DJ, Clegg JB. Globin genes in Micronesia: origins and affinities of Pacific Island peoples. Am J Hum Genet 1990; 46:144-155.
50. Pawley A, Green R. Dating the dispersal of the Oceanic languages. Oceanic Linguistics 1973; 12:1-67.
51. Pawley A, Ross M. Austronesian historical linguistics and culture history. Annu Rev Anthropol 1993; 22:425-459.
52. Persson I, Aklillu E, Rodrigues F, Bertilsson L, Ingelman-Sundberg M. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians. Pharmacogenetics 1996; 6:521-526.
53. Radloff PH, Philipps J, Nkeyi M, Hutchinson D, Kremsner PG. Atovaquone and proguanil for Plasmodium falciparum malaria. Lancet 1996; 347:1511-1514.
54. Lys intergenic 9 base pair deletion in human mitochondrial DNAs from the Pacific. Mol Biol Evol 1995; 12:604-615.
55. Roberts-Thomson JM, Martinson JJ, Norwich JT, Harding RM, Clegg JB, Boettcher B. An ancient common origin of aboriginal Australians and New Guinea Highlanders is supported by α-globin haplotype analysis. Am J Hum Genet 1996; 58:1017-1024.
56. Roh H-K, Dahl M-L, Tybring G, Yamada H, Cha Y-N, Bertilsson L. CYP2C19 genotype and phenotype determined by omeprazole in a Korean population. Pharmacogenetics 1996; 6:547-551.
57. Serjeantson SW. Migration and admixture in the Pacific: insights provided by human leucocyte antigens. In: Kirk R, Szathmary E, editors. Out of Asia: peopling the Americas and the Pacific. Canberra: The Journal of Pacific History; 1985. pp. 133-145.
58. Serjeantson SW, Kirk RL, Booth PB. Linguistic and genetic differentiation in New Guinea. J Hum Evol. 1983; 12:77-92.
59. Setiabudy R, Kusaka M, Chiba K, Darmansjah I, Ishizaki T. Dapsone N-acetylation, metoprolol β-hydroxylation, and S-mephenytoin 4-hydroxylation polymorphisms in an Indonesian population: a cocktail and extended phenotyping assessment trial. Clin Pharmacol Ther 1994; 56:142-153.
60. Smouse PE, Long JC. Matrix correlation analysis in anthropology and genetics. Yearbook of Physical Anthropology 1992; 35:187-213.
61. Sohn D-R, Kobayashi K, Chiba K, Lee K-H, Shin S-G, Ishizaki T. Disposition kinetics and metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992; 262:1195-1202.
62. Sykes B, Leiboff A, Low-Beer J, Tetzner S, Richards M. The origins of the Polynesians: an interpretation from mitochondrial lineage analysis. Am J Hum Genet 1995; 57:1463-1475.
63. Terrell J. History as a family tree, history as an entangled bank: constructing images and interpretations of prehistory in the South Pacific. Antiquity 1988; 62:642-657.
64. Uchida JY, Kasahara T, Bobogare A, Saefafia S, Kere N, Kawabata M, et al. The prevalence of falciparum malaria in the Solomon Islands investigated by a filter paper disk-PCR method. Jpn J Parasitol 1995; 44:119-127.
65. Ward SA, Helsby NA, Skjelbo E, Brosen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 1991; 31:689-692.
66. Wedlund PJ. Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. Clin Pharmacol Ther 1984; 36:773-780.
67. Weightman B. Agriculture in Vanuatu: a historical review. Surrey: British Friends of Vanuatu; 1989.
68. Wickler S, Spriggs M. Pleistocene human occupation of the Solomon Islands, Melanesia. Antiquity 1988; 62:703-706.
69. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. In: Kalow W, editor. Pharmacogenetics of drug metabolism. New York: Pergamon Press: 1992. pp. 657-685.
70. Wrighton SA, Stevens JC, Becker GW, VandenBranden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993; 306:240-245.
71. Xiao Z-S, Goldstein JA, Xie H-G, Blaisdell J, Wang W, Jiang C-H, et al. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele. J Pharmacol Exp Ther 1997; 281:604-609.